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One of the markers commonly used to identify tumor-
suppressor genes is the frequent loss of heterozygosity
(LOH) at a particular locus in tumor samples, indicating
that at least one of the alleles has been deleted. LOH at
chromosome 10q23 has been detected in ∼75% of glio-
blastomas and in ∼60% of advanced–prostate cancer
samples (reviewed in Li et al. 1997; Steck et al. 1997),
suggesting the presence of a tumor suppressor at this
locus. In fact, reintroduction of this region of chromo-
some 10 into glioblastoma cell lines resulted in a loss of
tumorigenicity in nude mice (Pershouse et al. 1993; Steck
et al. 1995). Recently, a candidate tumor-suppressor
gene, termed “PTEN” (“phosphatase and tensin homo-
logue deleted from chromosome 10”) or “MMAC1”
(“mutated in multiple advanced cancers”), has been iso-
lated from chromosome 10q23 (Li et al. 1997; Steck et
al. 1997). Importantly, in the majority of glioblastoma
samples in which only one allele had been deleted, the
other allele contained point mutations or small deletions,
suggesting that disruption of both alleles is necessary for
the formation of glioblastomas. Although the sample
sizes used currently are small, LOH and/or point mu-
tations have been found in PTEN in a growing number
of tumor samples, including ∼50% of endometrial can-
cers (Tashiro et al. 1997), suggesting that disruption of
PTEN is necessary for the development of specific forms
of cancer.
Strong evidence that PTEN is a bona fide tumor sup-
pressor comes from a recent flurry of papers that have
identified germ-line mutations of PTEN in three related,
inheritable, neoplastic disorders: Cowden disease, Lher-
mitte-Duclos disease, and Bannayan-Zonana syndrome
(Liaw et al. 1997; Marsh et al. 1997; Nelen et al. 1997).
All these disorders share similar pathological traits, such
as the formation of multiple benign tumors (mostly ha-
martomas) and an increased incidence of malignant can-
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cers (Eng et al. 1994). Lhermitte-Duclos disease has ad-
ditional pathologies, such as mental retardation and
macrocephaly, whereas Bannayan-Zonana syndrome
also includes lipomatosis and speckled penis and has an
earlier onset of the disease (Grolin et al. 1992). The
nonneoplastic pathologies seen in Cowden disease, Lher-
mitte-Duclos disease, and Bannayan-Zonana syndrome
also indicate that PTEN functions during normal
development.
One of the interesting aspects of PTEN is that it shares
homology with the family of protein tyrosine phospha-
tases (PTPs) as well as with the cytoskeletal protein ten-
sin (Li et al. 1997; Steck et al. 1997). Biochemical anal-
ysis of PTEN has revealed that it is a member of the
family of dual-specificity protein phosphatases (DSPs)
that dephosphorylate serine, threonine, and tyrosine res-
idues (Myers et al. 1997). Significantly, naturally occur-
ring point mutations isolated from tumor samples, as
well as from tissue explants from patients with Ban-
nayan-Zonana syndrome, resulted in pronounced inhi-
bition of phosphatase activity, indicating that this activ-
ity is necessary in order for PTEN to function as a tumor
suppressor (Myers et al. 1997).
The identification of PTEN as the tumor suppressor
residing on 10q23 has generated a great deal of interest.
PTEN represents a tumor suppressor with a defined en-
zymatic function, and it represents the first PTP to be
implicated as a bona fide tumor suppressor. A large num-
ber of protein tyrosine kinases (PTKs) have been impli-
cated as oncogenes, and disruption of the signaling com-
ponents downstream of PTKs has been associated with
the transformed phenotype. Since the initial purification
and cloning of the PTP family, PTPs have been impli-
cated in the inhibition of cell growth, and it has become
apparent that PTPs that are the natural antagonists of
the growth-promoting PTKs have been identified. In
fact, treatment of normal rat kidney cells with an in-
hibitor of cellular PTPs resulted in transformation (Klar-
lund 1985), demonstrating the importance of this class
of enzymes in maintaining control of cell proliferation.
In addition to proliferation, PTPs have been implicated
in a variety of nonneoplastic diseases, including diabetes
(Begum et al. 1991) and myotubular myopathy (Laporte
et al. 1996), and are essential virulence factors for a
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number of microbrial pathogens (Andersson et al. 1996).
Furthermore, PTPs have been implicated in the regula-
tion of immune-cell function (Neel and Tonks 1997).
Structure and Function of PTPs
PTEN is a member of the PTP family of enzymes. The
entire family is characterized by the presence of a cat-
alytic signature motif, HCXXGXXRS/T. In both the
PTPs and the DSPs this motif is located within a con-
served secondary structure consisting of seven a-helices
and 10 b-sheets (Barford et al. 1995). The diversity of
the PTP family arises mostly from the sequences that
flank this conserved catalytic core and includes extra-
cellular ligand-binding domains and motifs for protein-
protein interaction that specifies subcellular localization
or motifs for the regulation of enzymatic activity (Zhang
et al. 1995). Subcellular targeting also may contribute
to substrate specificity, by restricting the potential cel-
lular targets. Conventional wisdom suggests that PTPs
are promiscuous, but recent evidence has clearly dem-
onstrated that the PTPs exhibit exceptional substrate
specificity in a cellular context (Flint et al. 1997). The
presence of transmembrane receptor–like PTPs (RPTPs)
suggests that, as with the regulation of the receptor ty-
rosine kinases, these RPTPs may be regulated by the
binding of ligands. In addition, many of the extracellular
domains have homology to cell-adhesion molecules, in-
dicating a role for these PTPs in the regulation of bio-
logical responses to the extracellular matrix or to cell-
cell contact. It is important to note that PTPs can exert
both positive and negative regulatory functions and in
some cases have been shown to be positive regulators
of cell proliferation. For example, two closely related
PTPs, SHP-1 and SHP-2 (src-homology domain 2–con-
taining phosphatase), have opposing effects on cell sig-
naling. SHP-1 acts to control cytokine signaling by
down-regulating the Janus family of PTKs, whereas
SHP-2 is necessary for the growth factor–dependent ac-
tivation of Ras (reviewed in Neel and Tonks 1997).
The PTPs and DSPs appear to utilize the same catalytic
mechanism. Dephosphorylation is initiated by the active-
site cysteine (located in the signature motif), which func-
tions as a nucleophile to attack the phosphorus atom of
the substrate, forming a thiol-phosphate intermediate.
Another conserved residue, an aspartic acid located ∼32
residues N-terminal to the catalytic cysteine, promotes
the release of the dephosphorylated substrate from the
enzyme-substrate complex. The active enzyme is regen-
erated by a water molecule, which attacks the thiol-
phosphate bond, liberating the phosphoryl group from
the catalytic cysteine (reviewed in Barford et al. 1995).
This reaction can proceed very quickly, with PTP1B un-
dergoing ∼2,000 catalytic cycles/min (Flint et al. 1997),
and the Yersinia PTP (YOP) can undergo an astonishing
90,000 catalytic cycles/min! Determination of the crystal
structures of PTPs and DSPs has revealed the structural
basis for the differences in amino acid specificity. In the
PTPs, this catalytic cysteine residue is located at the base
of a deep cleft (Barford et al. 1994a). The depth of this
cleft is equivalent to the length of a phosphotyrosine
residue. The much shorter phosphoseryl and phospho-
threonyl residues are unable to reach the base of the
cleft, where the nucleophilic attack by the invariant cys-
teine occurs, and therefore cannot be dephosphorylated.
On the other hand, the catalytic cysteine in the DSPs is
in a much shallower cleft that can accommodate all three
phosphorylated hydroxyl amino acids (Yuvaniyama et
al. 1996).
Substrate Specificity of PTEN
PTEN possesses intrinsic phosphatase activity and is
a member of the dual-specificity family of PTPs (Myers
et al. 1997). PTEN prefers extremely acidic substrates,
exhibiting almost 50 times more activity toward poly-
acidic substrates than toward more traditional substrates
(Myers et al. 1997). The extreme selectivity of PTEN
toward acidic substrates in vitro suggests that the phys-
iological substrates also will be acidic. It is possible that
the acidic character may be manifested by proteins that
are phosphorylated on multiple sites. Although it is
tempting to propose that the physiological substrates of
PTEN will be phosphorylated on tyrosine residues, it is
important to realize that PTEN may recognize proteins
that are exclusively phosphorylated on serine and thre-
onine residues. In this context, it should be noted that
the DSP KAP-1 dephosphorylates cdk2 at Thr160 (Poon
and Hunter 1995). Although the substrates of PTEN in
vivo are likely to be proteinaceous, it has been shown
that members of this class of enzymes can dephosphor-
ylate a number of nonproteinaceous phosphoesters
(Howell et al. 1996), including the 5′ phosphate from
RNA (Takagi et al. 1997). However, RNA is unlikely to
be a target of PTEN, since the capping of RNA occurs
in the nucleus, and immunoflourescence analysis has in-
dicated a largely cytoplasmic localization of PTEN (Li
and Sun 1997; M. P. Myers, unpublished data). Nev-
ertheless, one should consider acidic nonproteinaceous
substrates, such as phosphoinositides, as potential tar-
gets for PTEN.
Effect of Point Mutations on PTEN Activity
Many naturally occurring point mutations in PTEN
have been uncovered from tumor samples, tumor cell
lines, and germ-line mutations that result in neoplastic
diseases (Li et al. 1997; Liaw et al. 1997; Marsh et al.
1997; Nelen et al. 1997; Rhei et al. 1997; Steck et al.
1997; Tashiro et al. 1997). A number of these point
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Figure 1 Locations of point mutations in PTEN. The locations
of missense mutations in PTEN are shown in boldface. Underlining
designates areas with a high frequency of mutation.
mutations have already been shown to be detrimental
to the enzymatic activity of PTEN (Myers et al. 1997).
It is possible, on the basis of the conserved secondary
structure and catalytic mechanism of the PTPs, to predict
how these point mutations disrupt PTEN activity. Point
mutations have been found in three major clusters in
PTEN (fig. 1). These clusters are also areas that are
highly conserved between PTEN and tensin. One cluster
surrounds the catalytic motif. Mutations in this region
of PTEN are predicted to disrupt enzymatic activity, ei-
ther by disrupting the catalytic cysteine directly or by
altering the orientation of this cysteine in the catalytic
cleft, thereby affecting its ability to attack the phospho-
rus atom (Barford et al. 1994b). The second cluster sur-
rounds the conserved aspartic acid residue required for
the release of the substrate from the PTP. The third clus-
ter, near the last conserved structural feature of the PTP
fold, an a-helix, also disrupts PTEN activity, which is
consistent with the proposed role of these residues in
coordinating a water molecule that hydrolyzes the thiol-
phosphate bond, activating the enzyme for another
round of catalysis (Barford et al. 1995; Myers et al.
1997). In addition, a number of point mutations have
been found to be spaced throughout the N-terminus of
PTEN and are believed to abolish PTEN enzymatic ac-
tivity, by disrupting the overall secondary structure
rather than by specifically disrupting the domains nec-
essary for catalysis (Myers et al. 1997). In addition, two
point mutations were tested that did not result in a loss
in PTEN enzymatic activity. However, it has not been
determined whether these mutations adversely affect the
ability of PTEN to function inside cells, perhaps by al-
tering interactions with important regulatory molecules,
by altering the ability of PTEN to recognize its physi-
ological substrates, or by adversely affecting the stability
of the protein or the message.
It is currently unclear why germ-line mutations in
PTEN give rise to at least three related, yet distinctive,
disorders. Significantly, samples isolated from a Cowden
disease patient indicated that the wild-type allele is pres-
ent in nonaffected tissue but is lost in tumor samples,
indicating that the development of tumors is dependent
on the secondary mutation of the inherited wild-type
allele (Liaw et al. 1997). Although the sample size is
small, there does appear to be a correlation between the
severity of the disorder and the enzymatic activity of the
mutated allele (Myers et al. 1997), suggesting that some
of these mutations may result in partial-loss-of-function
alleles. Similarly, mutations in the RET protein tyrosine
kinase have been shown to give rise to at least four
different inheritable disorders (van Heyningen 1994).
However, other genetic loci that interact with PTEN also
may account for the range of phenotypes. Uncovering
these other loci will provide important insights into
PTEN function, since they are likely to encode members
of the same signaling pathway regulated by PTEN, such
as the protein kinase(s) that works in opposition to
PTEN.
Future Directions
Many lines of evidence support the classification of
PTEN as a tumor suppressor, especially the finding that
germ-line mutations in PTEN result in neoplastic dis-
orders. In addition, PTEN has been found to be mutated
in the majority of glioblastomas and advanced prostate
cancers and in roughly one-half of endometrial cancers
(Li et al. 1997; Steck et al. 1997; Tashiro et al. 1997).
However, disruptions in PTEN occur only rarely in
breast cancer and in other gynecological cancers (Tashiro
et al. 1997), suggesting that PTEN plays a significant
role in the development of only a subset of cancers.
Significantly, polymorphisms in PTEN appear to be rare,
and mutations that have been identified in PTEN have
only been found in neoplastic disorders, strengthening
the link between PTEN and neoplastic diseases (Li et al.
1997; Liaw et al. 1997; Marsh et al. 1997; Nelen et al.
1997). Determination of the prevalence of PTEN mu-
tations in different kinds of cancer will be necessary to
strengthen the statistical link between disruption of
PTEN and the formation of specific tumor types.
Analysis of tumor samples has resulted in a number
of insights into the potential function of PTEN. Disrup-
tion of PTEN appears to occur late during tumorigenesis,
indicating that PTEN is probably not the so-called trans-
forming event necessary to initiate malignant cell
growth. In the case of glioblastoma, LOH at chromo-
some 10 usually is associated with an amplification and
rearrangement of the epidermal growth factor (EGF) re-
ceptor (von Deimling et al. 1992), suggesting that am-
plification and activation of the EGF receptor was the
transforming event, whereas disruption of PTEN may
be required at a later stage of tumor progression, perhaps
for regulation of a cell-cycle checkpoint that is several
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steps downstream of the transforming event. However,
given the advanced stages at which LOH at chromosome
10q23 occurs in glioblastomas and in prostate cancer,
it seems likely that PTEN may function to modulate
other cellular processes, such as angiogenesis, that are
best detected in tumorigenicity rather than in transfor-
mation assays. The homology between PTEN and the
cytoskeletal protein tensin suggests that the targets of
PTEN may be cytoskeletal. Indeed, a growing body of
evidence indicates an important role for tyrosine phos-
phorylation in the regulation of cytoskeletal function
and the importance of cytoskeletal changes during on-
cogenesis (Cobb and Parsons 1993; Chrzanowska-Wod-
nicka and Burridge 1994).
The reversible nature of protein phosphorylation in-
dicates that PTEN will function as a regulatory molecule
that acts in opposition to a kinase. Fundamental insights
into the biological function of PTEN will be revealed
following the identification of its physiological sub-
strates. The identity of these substrates will not only
indicate which cellular signaling pathways are normally
regulated by PTEN but also may lead to the identifi-
cation of the potentially oncogenic kinase(s) that is an-
tagonized by PTEN and eventually may lead to the char-
acterization of the entire signaling pathway. There are
precedents to illustrate that PTPs function to attenuate
signals that normally promote such fundamental re-
sponses as growth and proliferation. By removing phos-
phate, these PTPs act to maintain the balance between
an appropriate cellular response to a stimulus and an
aberrant, hyperresponsive state that promotes the dis-
ease phenotype. Determination of the mechanism by
which the opposing forces of PTEN and its antithetic
protein kinase function in regulating cellular signaling
will provide insights into the maintenance of normal cell
physiology and how this is subverted in cancer.
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